Small-molecule modulators of PXR and CAR

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1859, Issue 9, 2016, Pages 1141-1154

  Chai, Sergio C ^a   Cherian, Milu T ^a   Wang, Yue Ming ^a   Chen, Taosheng ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Binding promiscuity; CAR; Detoxification; PXR; Small molecule; Xenobiotic

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; HORMONE RECEPTOR AFFECTING AGENT; HORMONE RECEPTOR BLOCKING AGENT; PREGNANE X RECEPTOR; XENOBIOTIC AGENT; CAMPTOTHECIN; CELL RECEPTOR; COUMESTROL; KETOCONAZOLE; METFORMIN; MOLECULAR LIBRARY; PROTEIN BINDING; STEROID RECEPTOR;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; GENE EXPRESSION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPECIES DIFFERENCE; STRUCTURE ANALYSIS; AGONISTS; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG INACTIVATION; ENERGY METABOLISM; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CAMPTOTHECIN; COUMESTROL; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; INACTIVATION, METABOLIC; KETOCONAZOLE; LIVER; METFORMIN; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84959567417     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2016.02.013     Document Type: Article

References (158)

1. [1] Willson, T.M., Kliewer, S.A., PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1 (2002), 259–266.
2. [2] Wang, Y.M., Ong, S.S., Chai, S.C., Chen, T.S., Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8 (2012), 803–817.
3. [3] Johnson, C.H., Patterson, A.D., Idle, J.R., Gonzalez, F.J., Xenobiotic metabolomics: major impact on the metabolome. Annu. Rev. Pharmacol. 52 (2012), 37–56.
4. [4] Tolson, A.H., Wang, H.B., Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliv. Rev. 62 (2010), 1238–1249.
5. [5] Wang, Y.M., Lin, W.W., Chai, S.C., Wu, J., Ong, S.S., Schuetz, E.G., Chen, T.S., Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol. Appl. Pharmacol. 272 (2013), 96–107.
6. [6] Lin, W.W., Wu, J., Dong, H.Q., Bouck, D., Zeng, F.Y., Chen, T.S., Cyclin-dependent kinase 2 negatively regulates human pregnane X receptor-mediated CYP3A4 gene expression in HepG2 liver carcinoma cells. J. Biol. Chem. 283 (2008), 30650–30657.
7. [7] Lichti-Kaiser, K., Brobst, D., Xu, C.S., Staudinger, J.L., A systematic analysis of predicted phosphorylation sites within the human pregnane X receptor protein. J. Pharmacol. Exp. Ther. 331 (2009), 65–76.
8. [8] Pondugula, S.R., Brimer-Cline, C., Wu, J., Schuetz, E.G., Tyagi, R.K., Chen, T.S., A phosphomimetic mutation at threonine-57 abolishes transactivation activity and alters nuclear localization pattern of human pregnane X receptor. Drug Metab. Dispos. 37 (2009), 719–730.
9. [9] Doricakova, A., Novotna, A., Vrzal, R., Pavek, P., Dvorak, Z., The role of residues T248, Y249 and T422 in the function of human pregnane X receptor. Arch. Toxicol. 87 (2013), 291–301.
10. [10] Elias, A., High, A.A., Mishra, A., Ong, S.S., Wu, J., Peng, J.M., Chen, T.S., Identification and characterization of phosphorylation sites within the pregnane X receptor protein. Biochem. Pharmacol. 87 (2014), 360–370.
11. [11] Chen, T.S., Overcoming drug resistance by regulating nuclear receptors. Adv. Drug Deliv. Rev. 62 (2010), 1257–1264.
12. [12] Wang, Y.M., Chai, S.C., Lin, W.W., Chai, X.J., Elias, A., Wu, J., Ong, S.S., Pondugula, S.R., Beard, J.A., Schuetz, E.G., Zeng, S., Xie, W., Chen, T.S., Serine 350 of human pregnane X receptor is crucial for its heterodimerization with retinoid X receptor alpha and transactivation of target genes in vitro and in vivo. Biochem. Pharmacol. 96 (2015), 357–368.
13. [13] Sinz, M., Kim, S., Zhu, Z.R., Chen, T.S., Anthony, M., Dickinson, K., Rodrigues, A.D., Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr. Drug Metab. 7 (2006), 375–388.
14. [14] Sinz, M.W., Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug–drug interactions in drug development. Drug Metab. Rev. 45 (2013), 3–14.
15. [15] Wang, Y.M., Chai, S.C., Brewer, C.T., Chen, T.S., Pregnane X receptor and drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 10 (2014), 1521–1532.
16. [16] Ekins, S., Mirny, L., Schuetz, E.G., A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXR alpha, and LXR beta. Pharm. Res. 19 (2002), 1788–1800.
17. [17] Moore, L.B., Parks, D.J., Jones, S.A., Bledsoe, R.K., Consler, T.G., Stimmel, J.B., Goodwin, B., Liddle, C., Blanchard, S.G., Willson, T.M., Collins, J.L., Kliewer, S.A., Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275 (2000), 15122–15127.
18. [18] Xie, W., Barwick, J.L., Downes, M., Blumberg, B., Simon, C.M., Nelson, M.C., Neuschwander-Tetri, B.A., Bruntk, E.M., Guzelian, P.S., Evans, R.M., Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406 (2000), 435–439.
19. [19] Gong, H.B., Singh, S.V., Singh, S.P., Mu, Y., Lee, J.H., Saini, S.P.S., Toma, D., Ren, S.R., Kagan, V.E., Day, B.W., Zimniak, P., Xie, W., Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol. Endocrinol. 20 (2006), 279–290.
20. [20] Ma, X., Shah, Y., Cheung, C., Guo, G.L., Feigenbaum, L., Krausz, K.W., Idle, J.R., Gonzalez, F.J., The pregnane X receptor gene-humanized mouse: a model for investigating drug–drug interactions mediated by cytochromes P450 3A. Drug Metab. Dispos. 35 (2007), 194–200.
21. [21] Ma, X., Cheung, C., Krausz, K.W., Shah, Y.M., Wang, T., Idle, J.R., Gonzalez, F.J., A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab. Dispos. 36 (2008), 2506–2512.
22. [22] Scheer, N., Ross, J., Rode, A., Zevnik, B., Niehaves, S., Faust, N., Wolf, C.R., A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J. Clin. Invest. 118 (2008), 3228–3239.
23. [23] Igarashi, K., Kitajima, S., Aisaki, K., Tanemura, K., Taquahashi, Y., Moriyama, N., Ikeno, E., Matsuda, N., Saga, Y., Blumberg, B., Kanno, J., Development of humanized steroid and xenobiotic receptor mouse by homologous knock-in of the human steroid and xenobiotic receptor ligand binding domain sequence. J. Toxicol. Sci. 37 (2012), 373–380.
24. [24] Cheng, J., Shah, Y.M., Gonzalez, F.J., Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33 (2012), 323–330.
25. [25] Langmann, T., Moehle, C., Mauerer, R., Scharl, M., Liebisch, G., Zahn, A., Stremmel, W., Schmitz, G., Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127 (2004), 26–40.
26. [26] Dring, M.M., Goulding, C.A., Trimble, V.I., Keegan, D., Ryan, A.W., Brophy, K.M., Smyth, C.M., Keeling, P.W.N., O'Donoghue, D., O'Sullivan, M., O'Morain, C., Mahmud, N., Wikstrom, A.C., Kelleher, D., McManus, R., The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130 (2006), 341–348.
27. [27] Cheng, J., Shah, Y.M., Ma, X.C., Pang, X.Y., Tanaka, T., Kodama, T., Krausz, K.W., Gonzalez, F.J., Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 335 (2010), 32–41.
28. [28] Khan, K.J., Ullman, T.A., Ford, A.C., Abreu, M.T., Abadir, A., Marshall, J.K., Talley, N.J., Moayyedi, P., Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106 (2011), 661–673.
29. [29] Zhou, C., Tabb, M.M., Nelson, E.L., Grun, F., Verma, S., Sadatrafiei, A., Lin, M., Mallick, S., Forman, B.M., Thummel, K.E., Blumberg, B., Mutual repression between steroid and xenobiotic receptor and NF-kappa B signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116 (2006), 2280–2289.
30. [30] Sepe, V., Ummarino, R., D'Auria, M.V., Mencarelli, A., D'Amore, C., Renga, B., Zampella, A., Fiorucci, S., Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J. Med. Chem. 54 (2011), 4590–4599.
31. [31] Burk, O., Arnold, K.A., Nussler, A.K., Schaeffeler, E., Efimova, E., Avery, B.A., Avery, M.A., Fromm, M.F., Eichelbaum, M., Antimalarial artemisinin drugs induce cytochrome p450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67 (2005), 1954–1965.
32. [32] Hu, D.H., Wang, Y.G., Chen, Z.W., Ma, Z.C., You, Q., Zhang, X.X., Zhou, T., Xiao, Y., Liang, Q.D., Tan, H.L., Xiao, C.R., Tang, X.L., Zhang, B.L., Gao, Y., Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor. Eur. J. Pharmacol. 738 (2014), 273–284.
33. [33] Dou, W., Zhang, J.J., Zhang, E.Y., Sun, A.N., Ding, L.L., Chou, G.X., Wang, Z.T., Mani, S., Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-kappa B signaling pathway. J. Pharmacol. Exp. Ther. 345 (2013), 473–482.
34. [34] Dou, W., Zhang, J.J., Li, H., Kortagere, S., Sun, K., Ding, L.L., Ren, G.Y., Wang, Z.T., Mani, S., Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J. Nutr. Biochem. 25 (2014), 923–933.
35. [35] Lau, A.J., Chang, T.K.H., 3-Hydroxyflavone and structural analogues differentially activate pregnane X receptor: implication for inflammatory bowel disease. Pharmacol. Res. 100 (2015), 64–72.
36. [36] Ma, X.C., Shah, Y.M., Guo, G.L., Wang, T., Krausz, K.W., Idle, J.R., Gonzalez, F.J., Rifaximin is a gut-specific human pregnane X receptor activator. J. Pharmacol. Exp. Ther. 322 (2007), 391–398.
37. [37] Gotoh, S., Negishi, M., Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis. Sci. Rep., 5, 2015, 14076.
38. [38] Synold, T.W., Dussault, I., Forman, B.M., The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7 (2001), 584–590.
39. [39] Aune, G.J., Furuta, T., Pommier, Y., Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anticancer Drugs 13 (2002), 545–555.
40. [40] van Kesteren, C., de Vooght, M.M.M., Lopez-Lazaro, L., Mathot, R.A.A., Schellens, J.H.M., Jimeno, J.M., Beijnen, J.H., Yondelis (R) (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 14 (2003), 487–502.
41. [41] Zhou, C.C., Poulton, E.J., Grun, F., Bammler, T.K., Blumberg, B., Thummel, K.E., Eaton, D.L., The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 71 (2007), 220–229.
42. [42] Ekins, S., Kholodovych, V., Ai, N., Sinz, M., Gal, J., Gera, L., Welsh, W.J., Bachmann, K., Mani, S., Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol. Pharmacol. 74 (2008), 662–672.
43. [43] Poulton, E.J., Levy, L., Lampe, J.W., Shen, D.D., Tracy, J., Shuhart, M.C., Thummel, K.E., Eaton, D.L., Sulforaphane is not an effective antagonist of the human pregnane X-receptor in vivo. Toxicol. Appl. Pharmacol. 266 (2013), 122–131.
44. [44] Atwell, L.L., Zhang, Z., Mori, M., Farris, P.E., Vetto, J.T., Naik, A.M., Oh, K.Y., Thuillier, P., Ho, E., Shannon, J., Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy. Cancer Prev. Res. (Phila.) 8 (2015), 1184–1191.
45. [45] Wang, H.W., Li, H., Moore, L.B., Johnson, M.D.L., Maglich, J.M., Goodwin, B., Ittoop, O.R.R., Wisely, B., Creech, K., Parks, D.J., Collins, J.L., Willson, T.M., Kalpana, G.V., Venkatesh, M., Xie, W., Cho, S.Y., Roboz, J., Redinbo, M., Moore, J.T., Mani, S., The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol. Endocrinol. 22 (2008), 838–857.
46. [46] Lim, Y.P., Ma, C.Y., Liu, C.L., Lin, Y.H., Hu, M.L., Chen, J.J., Hung, D.Z., Hsieh, W.T., Huang, J.D., Sesamin: a naturally occurring lignan inhibits CYP3A4 by antagonizing the pregnane X receptor activation. Evid. Based Complement. Alternat. Med., 242810, 2012.
47. [47] Chen, Y.K., Tang, Y., Robbins, G.T., Nie, D.T., Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J. Pharmacol. Exp. Ther. 334 (2010), 999–1008.
48. [48] Mani, S., Dou, W., Redinbo, M.R., PXR antagonists and implication in drug metabolism. Drug Metab. Rev. 45 (2013), 60–72.
49. [49] Takeshita, A., Taguchi, M., Koibuchi, N., Ozawa, Y., Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J. Biol. Chem. 277 (2002), 32453–32458.
50. [50] Ekins, S., Chang, C., Mani, S., Krasowski, M.D., Reschly, E.J., Iyer, M., Kholodovych, V., Ai, N., Welsh, W.J., Sinz, M., Swaan, P.W., Patel, R., Bachmann, K., Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol. 72 (2007), 592–603.
51. [51] Wang, H.W., Huang, H.Y., Li, H., Teotico, D.G., Sinz, M., Baker, S.D., Staudinger, J., Kalpana, G., Redinbo, M.R., Mani, S., Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res. 13 (2007), 2488–2495.
52. [52] Huang, H., Wang, H., Sinz, M., Zoeckler, M., Staudinger, J., Redinbo, M.R., Teotico, D.G., Locker, J., Kalpana, G.V., Mani, S., Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26 (2007), 258–268.
53. [53] Li, H., Redinbo, M.R., Venkatesh, M., Ekins, S., Chaudhry, A., Bloch, N., Negassa, A., Mukherjee, P., Kalpana, G., Mani, S., Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J. Biol. Chem. 288 (2013), 13655–13668.
54. [54] Das, B.C., Madhukumar, A.V., Anguiano, J., Kim, S., Sinz, M., Zvyaga, T.A., Power, E.C., Ganellin, C.R., Mani, S., Synthesis of novel ketoconazole derivatives as inhibitors of the human pregnane X receptor (PXR; NR1I2; also termed SXR, PAR). Bioorg. Med. Chem. Lett. 18 (2008), 3974–3977.
55. [55] Venkatesh, M., Wang, H.W., Cayer, J., Leroux, M., Salvail, D., Das, B., Wrobel, J.E., Mani, S., In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol. Pharmacol. 80 (2011), 124–135.
56. [56] Baes, M., Gulick, T., Choi, H.S., Martinoli, M.G., Simha, D., Moore, D.D., A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol. 14 (1994), 1544–1552.
57. [57] Choi, H.S., Chung, M., Tzameli, I., Simha, D., Lee, Y.K., Seol, W., Moore, D.D., Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J. Biol. Chem. 272 (1997), 23565–23571.
58. [58] Honkakoski, P., Zelko, I., Sueyoshi, T., Negishi, M., The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol. Cell. Biol. 18 (1998), 5652–5658.
59. [59] Wang, H., Faucette, S., Sueyoshi, T., Moore, R., Ferguson, S., Negishi, M., LeCluyse, E.L., A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J. Biol. Chem. 278 (2003), 14146–14152.
60. [60] Masson, D., Qatanani, M., Sberna, A.L., Xiao, R., Pais de Barros, J.P., Grober, J., Deckert, V., Athias, A., Gambert, P., Lagrost, L., Moore, D.D., Assem, M., Activation of the constitutive androstane receptor decreases HDL in wild-type and human apoA-I transgenic mice. J. Lipid Res. 49 (2008), 1682–1691.
61. [61] Wei, P., Zhang, J., Dowhan, D.H., Han, Y., Moore, D.D., Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J. 2 (2002), 117–126.
62. [62] Xu, R.X., Lambert, M.H., Wisely, B.B., Warren, E.N., Weinert, E.E., Waitt, G.M., Williams, J.D., Collins, J.L., Moore, L.B., Willson, T.M., Moore, J.T., A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol. Cell 16 (2004), 919–928.
63. [63] Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., Downey, A., Mudra, D., Graham, R., Carroll, K., Xie, J., Madan, A., Parkinson, A., Christ, D., Selling, B., LeCluyse, E., Gan, L.S., CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30 (2002), 795–804.
64. [64] Tamasi, V., Juvan, P., Beer, M., Rozman, D., Meyer, U.A., Transcriptional activation of PPARalpha by phenobarbital in the absence of CAR and PXR. Mol. Pharm. 6 (2009), 1573–1581.
65. [65] Roth, A., Looser, R., Kaufmann, M., Blattler, S.M., Rencurel, F., Huang, W., Moore, D.D., Meyer, U.A., Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol. 73 (2008), 1282–1289.
66. [66] Li, L., Sinz, M.W., Zimmermann, K., Wang, H., An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism. J. Pharmacol. Exp. Ther. 340 (2012), 688–697.
67. [67] Goodwin, B., Hodgson, E., D'Costa, D.J., Robertson, G.R., Liddle, C., Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62 (2002), 359–365.
68. [68] Li, L., Chen, T., Stanton, J.D., Sueyoshi, T., Negishi, M., Wang, H., The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol. Pharmacol. 74 (2008), 443–453.
69. [69] Huang, W., Zhang, J., Chua, S.S., Qatanani, M., Han, Y., Granata, R., Moore, D.D., Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4156–4161.
70. [70] Kast, H.R., Goodwin, B., Tarr, P.T., Jones, S.A., Anisfeld, A.M., Stoltz, C.M., Tontonoz, P., Kliewer, S., Willson, T.M., Edwards, P.A., Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 277 (2002), 2908–2915.
71. [71] Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q.H., Owens, I.S., Negishi, M., Sueyoshi, T., The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33 (2001), 1232–1238.
72. [72] Ueda, A., Hamadeh, H.K., Webb, H.K., Yamamoto, Y., Sueyoshi, T., Afshari, C.A., Lehmann, J.M., Negishi, M., Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61 (2002), 1–6.
73. [73] Fang, H.L., Strom, S.C., Cai, H., Falany, C.N., Kocarek, T.A., Runge-Morris, M., Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 67 (2005), 1257–1267.
74. [74] Sugatani, J., Sueyoshi, T., Negishi, M., Miwa, M., Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Helmut, S., Lester, P., (eds.) Methods in Enzymology, 400, 2005, Academic Press, Waltham, Massachusetts, 92–104.
75. [75] Qatanani, M., Zhang, J., Moore, D.D., Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 146 (2005), 995–1002.
76. [76] Mathas, M., Burk, O., Qiu, H., Nusshag, C., Godtel-Armbrust, U., Baranyai, D., Deng, S., Romer, K., Nem, D., Windshugel, B., Wojnowski, L., Evolutionary history and functional characterization of the amphibian xenosensor CAR. Mol. Endocrinol. 26 (2012), 14–26.
77. [77] Kanno, Y., Aoki, S., Mochizuki, M., Mori, E., Nakahama, T., Inouye, Y., Expression of constitutive androstane receptor splice variants in rat liver and lung and their functional properties. Biol. Pharm. Bull. 28 (2005), 2058–2062.
78. [78] Gray, M.A., Peacock, J.N., Squires, E.J., Characterization of the porcine constitutive androstane receptor (CAR) and its splice variants. Xenobiotica 39 (2009), 915–930.
79. [79] DeKeyser, J.G., Stagliano, M.C., Auerbach, S.S., Prabhu, K.S., Jones, A.D., Omiecinski, C.J., Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive androstane receptor splice variant CAR2. Mol. Pharmacol. 75 (2009), 1005–1013.
80. [80] Forman, B.M., Tzameli, I., Choi, H.S., Chen, J., Simha, D., Seol, W., Evans, R.M., Moore, D.D., Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 395 (1998), 612–615.
81. [81] Tzameli, I., Pissios, P., Schuetz, E.G., Moore, D.D., The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol. Cell. Biol. 20 (2000), 2951–2958.
82. [82] Lynch, C., Pan, Y., Li, L., Heyward, S., Moeller, T., Swaan, P.W., Wang, H., Activation of the constitutive androstane receptor inhibits gluconeogenesis without affecting lipogenesis or fatty acid synthesis in human hepatocytes. Toxicol. Appl. Pharmacol. 279 (2014), 33–42.
83. [83] Lake, B.G., Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 39 (2009), 582–596.
84. [84] Yamada, T., Okuda, Y., Kushida, M., Sumida, K., Takeuchi, H., Nagahori, H., Fukuda, T., Lake, B.G., Cohen, S.M., Kawamura, S., Human hepatocytes support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogen sodium phenobarbital in an in vivo study using a chimeric mouse with humanized liver. Toxicol. Sci. 142 (2014), 137–157.
85. [85] Lamba, J.K., Lamba, V., Yasuda, K., Lin, Y.S., Assem, M., Thompson, E., Strom, S., Schuetz, E., Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J. Pharmacol. Exp. Ther. 311 (2004), 811–821.
86. [86] Shmueli, O., Horn-Saban, S., Chalifa-Caspi, V., Shmoish, M., Ophir, R., Benjamin-Rodrig, H., Safran, M., Domany, E., D. and Lancet, GeneNote: whole genome expression profiles in normal human tissues. C. R. Biol. 326 (2003), 1067–1072.
87. [87] Auerbach, S.S., Ramsden, R., Stoner, M.A., Verlinde, C., Hassett, C., Omiecinski, C.J., Alternatively spliced isoforms of the human constitutive androstane receptor. Nucleic Acids Res. 31 (2003), 3194–3207.
88. [88] Kanno, Y., Aoki, S., Nakahama, T., Inouye, Y., Role of the defective splicing of mRNA in the lack of pulmonary expression of constitutively active receptor in rat. J. Health Sci. 49 (2003), 541–546.
89. [89] Arnold, K.A., Eichelbaum, M., Burk, O., Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor. Nucl. Recept., 2, 2004, 1.
90. [90] Jinno, H., Tanaka-Kagawa, T., Hanioka, N., Ishida, S., Saeki, M., Soyama, A., Itoda, M., Nishimura, T., Saito, Y., Ozawa, S., Ando, M., Sawada, J., Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol. Pharmacol. 65 (2004), 496–502.
91. [91] Ross, J., Plummer, S.M., Rode, A., Scheer, N., Bower, C.C., Vogel, O., Henderson, C.J., Wolf, C.R., Elcombe, C.R., Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 116 (2010), 452–466.
92. [92] Savkur, R.S., Wu, Y., Bramlett, K.S., Wang, M., Yao, S., Perkins, D., Totten, M., Searfoss, G. 3rd, Ryan, T.P., Su, E.W., Burris, T.P., Alternative splicing within the ligand binding domain of the human constitutive androstane receptor. Mol. Genet. Metab. 80 (2003), 216–226.
93. [93] Auerbach, S.S., Dekeyser, J.G., Stoner, M.A., Omiecinski, C.J., CAR2 displays unique ligand binding and RXRalpha heterodimerization characteristics. Drug Metab. Dispos. 35 (2007), 428–439.
94. [94] Ikeda, S., Kurose, K., Jinno, H., Sai, K., Ozawa, S., Hasegawa, R., Komamura, K., Kotake, T., Morishita, H., Kamakura, S., Kitakaze, M., Tomoike, H., Tamura, T., Yamamoto, N., Kunitoh, H., Yamada, Y., Ohe, Y., Shimada, Y., Shirao, K., Kubota, K., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Saito, Y., Sawada, J., Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol. Genet. Metab. 86 (2005), 314–319.
95. [95] Lau, A.J., Chang, T.K., Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol. Appl. Pharmacol. 277 (2014), 221–230.
96. [96] Omiecinski, C.J., Coslo, D.M., Chen, T., Laurenzana, E.M., Peffer, R.C., Multi-species analyses of direct activators of the constitutive androstane receptor. Toxicol. Sci. 123 (2011), 550–562.
97. [97] Sharma, D., Lau, A.J., Sherman, M.A., Chang, T.K., Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine. Br. J. Pharmacol. 172 (2014), 1263–1276.
98. [98] Lau, A.J., Chang, T.K., Indirect activation of the SV23 and SV24 splice variants of human constitutive androstane receptor: analysis with 3-hydroxyflavone and its analogues. Br. J. Pharmacol. 170 (2013), 403–414.
99. [99] DeKeyser, J.G., Laurenzana, E.M., Peterson, E.C., Chen, T., Omiecinski, C.J., Selective phthalate activation of naturally occurring human constitutive androstane receptor splice variants and the pregnane X receptor. Toxicol. Sci. 120 (2011), 381–391.
100. [100] Paul, K.B., Thompson, J.T., Simmons, S.O., Vanden Heuvel, J.P., Crofton, K.M., Evidence for triclosan-induced activation of human and rodent xenobiotic nuclear receptors. Toxicol. In Vitro 27 (2013), 2049–2060.
101. [101] Thompson, E.E., Kuttab-Boulos, H., Krasowski, M.D., Di Rienzo, A., Functional constraints on the constitutive androstane receptor inferred from human sequence variation and cross-species comparisons. Hum. Genomics 2 (2005), 168–178.
102. [102] Cortes, C.P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., la Porte, C.J., Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit. 35 (2013), 78–83.
103. [103] Urano, T., Usui, T., Shiraki, M., Ouchi, Y., Inoue, S., Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr. Gerontol. Int. 9 (2009), 235–241.
104. [104] Choi, E.J., Jang, Y.J., Cha, E.Y., Shin, J.G., Lee, S.S., Identification and characterization of novel alternative splice variants of human constitutive androstane receptor in liver samples of Koreans and Caucasians. Drug Metab. Dispos. 41 (2013), 888–896.
105. [105] Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., Negishi, M., The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274 (1999), 6043–6046.
106. [106] Wang, H., Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., LeCluyse, E., Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem. 279 (2004), 29295–29301.
107. [107] Carazo Fernandez, A., Smutny, T., Hyrsova, L., Berka, K., Pavek, P., Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR). Toxicol. Lett. 233 (2015), 68–77.
108. [108] Yueh, M.-F., Taniguchi, K., Chen, S., Evans, R.M., Hammock, B.D., Karin, M., Tukey, R.H., The commonly used antimicrobial additive triclosan is a liver tumor promoter. Proc. Natl. Acad. Sci. 111 (2014), 17200–17205.
109. [109] Zhang, J., Huang, W., Chua, S.S., Wei, P., Moore, D.D., Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298 (2002), 422–424.
110. [110] Yoshinari, K., Kobayashi, K., Moore, R., Kawamoto, T., Negishi, M., Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital. FEBS Lett. 548 (2003), 17–20.
111. [111] Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L., Perera, L., Rebolloso, Y., Sueyoshi, T., Negishi, M., Dephosphorylation of threonine 38 is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). J. Biol. Chem. 284 (2009), 34785–34792.
112. [112] Mutoh, S., Sobhany, M., Moore, R., Perera, L., Pedersen, L., Sueyoshi, T., Negishi, M., Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci. Signal., 6, 2013, ra31.
113. [113] Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K., Negishi, M., Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell. Biol. 19 (1999), 6318–6322.
114. [114] Joannard, F., Rissel, M., Gilot, D., Anderson, A., Orfila-Lefeuvre, L., Guillouzo, A., Atfi, A., Lagadic-Gossmann, D., Role for mitogen-activated protein kinases in phenobarbital-induced expression of cytochrome P450 2B in primary cultures of rat hepatocytes. Toxicol. Lett. 161 (2006), 61–72.
115. [115] Koike, C., Moore, R., Negishi, M., Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol. Pharmacol. 71 (2007), 1217–1221.
116. [116] Bauer, D., Wolfram, N., Kahl, G.F., Hirsch-Ernst, K.I., Transcriptional regulation of CYP2B1 induction in primary rat hepatocyte cultures: repression by epidermal growth factor is mediated via a distal enhancer region. Mol. Pharmacol. 65 (2004), 172–180.
117. [117] Li, H., Chen, T., Cottrell, J., Wang, H., Nuclear translocation of adenoviral-enhanced yellow fluorescent protein-tagged-human constitutive androstane receptor (hCAR): a novel tool for screening hCAR activators in human primary hepatocytes. Drug Metab. Dispos. 37 (2009), 1098–1106.
118. [118] Zelko, I., Sueyoshi, T., Kawamoto, T., Moore, R., Negishi, M., The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. Mol. Cell. Biol. 21 (2001), 2838–2846.
119. [119] Lynch, C., Zhao, J., Huang, R., Xiao, J., Li, L., Heyward, S., Xia, M., Wang, H., Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor. Sci. Rep., 5, 2015, 10405.
120. [120] Yang, H., Wang, H., Signaling control of the constitutive androstane receptor (CAR). Protein Cell 5 (2014), 113–123.
121. [121] Dong, B., Qatanani, M., Moore, D.D., Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 50 (2009), 622–629.
122. [122] Gao, J., He, J., Zhai, Y., Wada, T., Xie, W., The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J. Biol. Chem. 284 (2009), 25984–25992.
123. [123] Tamashiro, K.L., Terrillion, C.E., Hyun, J., Koenig, J.I., Moran, T.H., Prenatal stress or high-fat diet increases susceptibility to diet-induced obesity in rat offspring. Diabetes 58 (2009), 1116–1125.
124. [124] Lahtela, J.T., Arranto, A.J., Sotaniemi, E.A., Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 34 (1985), 911–916.
125. [125] Goerdt, C., Keith, M., Rubins, H.B., Effects of phenytoin on plasma high-density lipoprotein cholesterol levels in men with low levels of high-density lipoprotein cholesterol. J. Clin. Pharmacol. 35 (1995), 767–775.
126. [126] Pelkonen, R., Fogelholm, R., Nikkila, E.A., Increase in serum cholesterol during phenytoin treatment. Br. Med. J., 4, 1975, 85.
127. [127] Masuyama, H., Hiramatsu, Y., Treatment with a constitutive androstane receptor ligand ameliorates the signs of preeclampsia in high-fat diet-induced obese pregnant mice. Mol. Cell. Endocrinol. 348 (2012), 120–127.
128. [128] Wagner, M., Halilbasic, E., Marschall, H.U., Zollner, G., Fickert, P., Langner, C., Zatloukal, K., Denk, H., Trauner, M., CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42 (2005), 420–430.
129. [129] Zhang, J., Huang, W., Qatanani, M., Evans, R.M., Moore, D.D., The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 279 (2004), 49517–49522.
130. [130] Yamamoto, Y., Moore, R., Flavell, R.A., Lu, B., Negishi, M., Nuclear receptor CAR represses TNFα-induced cell death by interacting with the anti-apoptotic GADD45B. PLoS One, 5, 2010, e10121.
131. [131] Elcombe, C.R., Peffer, R.C., Wolf, D.C., Bailey, J., Bars, R., Bell, D., Cattley, R.C., Ferguson, S.S., Geter, D., Goetz, A., Goodman, J.I., Hester, S., Jacobs, A., Omiecinski, C.J., Schoeny, R., Xie, W., Lake, B.G., Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: a case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit. Rev. Toxicol. 44 (2014), 64–82.
132. [132] Wang, D., Li, L., Yang, H., Ferguson, S.S., Baer, M.R., Gartenhaus, R.B., Wang, H., The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood 121 (2013), 329–338.
133. [133] Fukumasu, H., Rochetti, A.L., Pires, P.R., Silva, E.R., Mesquita, L.G., Strefezzi, R.F., De Carvalho, D.D., Dagli, M.L., Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells. PLoS One, 9, 2014, e99484.
134. [134] Chakraborty, S., Kanakasabai, S., Bright, J.J., Constitutive androstane receptor agonist CITCO inhibits growth and expansion of brain tumour stem cells. Br. J. Cancer 104 (2011), 448–459.
135. [135] Wang, Y., Masuyama, H., Nobumoto, E., Zhang, G., Hiramatsu, Y., The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells. Biochem. Pharmacol. 90 (2014), 356–366.
136. [136] Watkins, R.E., Wisely, G.B., Moore, L.B., Collins, J.L., Lambert, M.H., Williams, S.P., Willson, T.M., Kliewer, S.A., Redinbo, M.R., The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292 (2001), 2329–2333.
137. [137] Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J.Y., Repa, J.J., Kliewer, S.A., Xu, H.E., The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol. Cell 16 (2004), 893–905.
138. [138] Shan, L., Vincent, J., Brunzelle, J.S., Dussault, I., Lin, M., Ianculescu, I., Sherman, M.A., Forman, B.M., Fernandez, E.J., Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol. Cell 16 (2004), 907–917.
139. [139] Noble, S.M., Carnahan, V.E., Moore, L.B., Luntz, T., Wang, H., Ittoop, O.R., Stimmel, J.B., Davis-Searles, P.R., Watkins, R.E., Wisely, G.B., LeCluyse, E., Tripathy, A., McDonnell, D.P., Redinbo, M.R., Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 45 (2006), 8579–8589.
140. [140] di Masi, A., De Marinis, E., Ascenzi, P., Marino, M., Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol. Aspects Med. 30 (2009), 297–343.
141. [141] Watkins, R.E., Davis-Searles, P.R., Lambert, M.H., Redinbo, M.R., Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 331 (2003), 815–828.
142. [142] Khan, J.A., Camac, D.M., Low, S., Tebben, A.J., WenseI, D.L., Wright, M.C., Su, J.L., Jenny, V., Das Gupta, R., Ruzanov, M., Russo, K.A., Bell, A., An, Y.M., Bryson, J.W., Gao, M.A., Gambhire, P., Baldwin, E.T., Gardner, D., Cavallaro, C.L., Duncia, J.V., Hynes, J., Developing adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. J. Mol. Biol. 427 (2015), 924–942.
143. [143] Xue, Y., Chao, E., Zuercher, W.J., Willson, T.M., Collins, J.L., Redinbo, M.R., Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg. Med. Chem. 15 (2007), 2156–2166.
144. [144] Cheng, Y., Redinbo, M.R., Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 20 (2011), 1713–1719.
145. [145] Xue, Y., Moore, L.B., Orans, J., Peng, L., Bencharit, S., Kliewer, S.A., Redinbo, M.R., Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol. Endocrinol. 21 (2007), 1028–1038.
146. [146] Teotico, D.G., Bischof, J.J., Peng, L., Kliewer, S.A., Redinbo, M.R., Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol. Pharmacol. 74 (2008), 1512–1520.
147. [147] Watkins, R.E., Maglich, J.M., Moore, L.B., Wisely, G.B., Noble, S.M., Davis-Searles, P.R., Lambert, M.H., Kliewer, S.A., Redinbo, M.R., 2.1 angstrom crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42 (2003), 1430–1438.
148. [148] Windshugel, B., Jyrkkarinne, J., Vanamo, J., Poso, A., Honkakoski, P., Sippl, W., Comparison of homology models and X-ray structures of the nuclear receptor CAR: assessing the structural basis of constitutive activity. J. Mol. Graph. Model. 25 (2007), 644–657.
149. [149] Moore, D.D., CAR: three new models for a problem child. Cell Metab. 1 (2005), 6–8.
150. [150] Wallace, B.D., Betts, L., Talmage, G., Pollet, R.M., Holman, N.S., Redinbo, M.R., Structural and functional analysis of the human nuclear xenobiotic receptor PXR in complex with RXR alpha. J. Mol. Biol. 425 (2013), 2561–2577.
151. [151] Chrencik, J.E., Orans, J., Moore, L.B., Xue, Y., Peng, L., Collins, J.L., Wisely, G.B., Lambert, M.H., Kliewer, S.A., Redinbo, M.R., Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol. Endocrinol. 19 (2005), 1125–1134.
152. [152] Delfosse, V., Dendele, B., Huet, T., Grimaldi, M., Boulahtouf, A., Gerbal-Chaloin, S., Beucher, B., Roecklin, D., Muller, C., Rahmani, R., Cavailles, V., Daujat-Chavanieu, M., Vivat, V., Pascussi, J.M., Balaguer, P., Bourguet, W., Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds. Nat. Commun., 6, 2015, 8089.
153. [153] Tabb, M.M., Kholodovych, V., Grun, F., Zhou, C.C., Welsh, W.J., Blumberg, B., Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ. Health Perspect. 112 (2004), 163–169.
154. [154] Kublbeck, J., Jyrkkarinne, J., Molnar, F., Kuningas, T., Patel, J., Windshugel, B., Nevalainen, T., Laitinen, T., Sippl, W., Poso, A., Honkakoski, P., New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol. Pharm. 8 (2011), 2424–2433.
155. [155] Krausova, L., Stejskaova, L., Wang, H.W., Vrzal, R., Dvorak, Z., Mani, S., Pavek, P., Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. Biochem. Pharmacol. 82 (2011), 1771–1780.
156. [156] Healan-Greenberg, C., Waring, J.F., Kempf, D.J., Blomme, E.A.G., Tirona, R.G., Kim, R.B., A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab. Dispos. 36 (2008), 500–507.
157. [157] Cherian, M.T., Lin, W.W., Wu, J., Chen, T.S., CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor. Mol. Pharmacol. 87 (2015), 878–889.
158. [158] Lin, W., Yang, L., Chai, S.C., Lu, Y., Chen, T., Development of CINPA1 analogs as novel and potent inverse agonists of constitutive androstane receptor. Eur. J. Med. Chem. 108 (2016), 505–528.